Skip to main content
JINLING PHARMACEUTICAL CO.,LTD logo

JINLING PHARMACEUTICAL CO.,LTD — Investor Relations & Filings

Ticker · 000919 ISIN · CNE0000010W5 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,771 across all filing types
Latest filing 2023-03-10 Proxy Solicitation & In…
Country CN China
Listing Shenzhen Stock Exchange 000919

About JINLING PHARMACEUTICAL CO.,LTD

https://www.jlyy1999.com

Jinling Pharmaceutical Co., Ltd. specializes in the research, development, manufacture, and sale of pharmaceutical products, with a focus on chemical drugs and traditional Chinese medicine preparations. The company’s product portfolio primarily targets cardiovascular and cerebrovascular diseases, anti-tumor treatments, and digestive system health. A prominent product in its lineup is the Mailuoning Injection, utilized for treating various vascular conditions. In addition to its manufacturing operations, the company is involved in the management and operation of medical institutions, integrating clinical services with pharmaceutical production. Its business model emphasizes the synergy between drug development and healthcare service delivery to provide integrated medical solutions.

Recent filings

Filing Released Lang Actions
金陵药业股份有限公司关于召开2023年第一次临时股东大会的提示性公告
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a detailed announcement regarding the convening of the 2023 first extraordinary general meeting (临时股东大会) of Jinling Pharmaceutical Co., Ltd. It includes information about the meeting date, voting procedures (both onsite and online), agenda items, and proxy voting instructions. The content focuses on the logistics and procedural details of the shareholders' meeting rather than financial results or management commentary. There is no financial data or report content, but rather a notice and instructions for shareholders to participate and vote on various proposals, including capital raising and board matters. This fits the definition of a Proxy Solicitation & Information Statement (PSI), which provides materials sent to shareholders to inform and request votes for meetings. The document is not a full Annual Report, Interim Report, or Earnings Release, nor is it a simple announcement of a report publication. It is also not a voting results declaration, but a pre-meeting solicitation and information document.
2023-03-10 Chinese
金陵药业股份有限公司关于收到控股股东关于公司2023年度向特定对象发行A股股票项目批复的公告
Capital/Financing Update Classification · 95% confidence The document is a short announcement (391 characters) regarding the approval of a specific issuance of A shares by the controlling shareholder. It mentions the receipt of an official approval document and confirms the agreement to subscribe cash for the issuance. There is no detailed financial data or comprehensive report content. The document is an update on a capital raising activity, specifically a share issuance to a particular party. According to the definitions, this fits best under 'Capital/Financing Update (CAP)' as it relates to company fundraising and capital structure changes. The document is not a full report, nor is it a regulatory filing or announcement of a report publication. Therefore, the classification is CAP with high confidence.
2023-03-10 Chinese
金陵药业股份有限公司关于控股子公司业绩承诺补偿涉及诉讼的进展公告
Legal Proceedings Report Classification · 95% confidence The document is an announcement regarding the progress of litigation involving the company and its controlling subsidiary. It details court case numbers, legal proceedings, and the status of lawsuits, including claims and counterclaims. There is no financial data, earnings information, or report publication mentioned. The content focuses solely on legal proceedings and updates on lawsuits. Therefore, this document fits the category of Legal Proceedings Report (LTR). The document length is short and it is not a report publication announcement or certification. Hence, the classification is LTR with high confidence.
2023-03-06 Chinese
金陵药业股份有限公司2023年度向特定对象发行A股股票预案
Capital/Financing Update Classification · 95% confidence The document is titled "2023 年度向特定对象发行 A 股股票预案" which translates to "2023 Annual Proposal for Private Placement of A Shares." It is a detailed plan regarding the issuance of A shares to specific investors, including background, purpose, issuance details, pricing, and regulatory approvals required. The document discusses the issuance scheme, the number of shares, pricing principles, and the intended use of proceeds. It is a comprehensive proposal related to capital raising through a private placement of shares. This fits the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities. The document is lengthy (15,000 characters) and contains substantive details about the financing plan, not merely an announcement or a brief summary. Therefore, it is not a Report Publication Announcement (RPA) or Regulatory Filing (RNS). It is not an Annual Report, Earnings Release, or any other category. Hence, the correct classification is CAP with high confidence.
2023-02-27 Chinese
金陵药业股份有限公司无需编制前次募集资金使用情况报告的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Jinling Pharmaceutical Co., Ltd. regarding the company's 2023 issuance of A shares to specific investors and the decision that no prior fundraising usage report is required. It references regulatory guidelines from the China Securities Regulatory Commission about fundraising reports and audit requirements. The document is short (730 characters) and serves as a formal announcement about a capital raising activity and compliance with reporting rules, rather than containing financial statements or detailed financial data. Therefore, it is best classified as a Capital/Financing Update (CAP).
2023-02-27 Chinese
金陵药业股份有限公司监事会关于公司非公开发行A股股票相关事项的书面审核意见
Capital/Financing Update Classification · 95% confidence The document is a written supervisory board opinion regarding the company's issuance of A shares to specific investors. It discusses compliance with laws and regulations, the issuance plan, pricing fairness, related party transactions, shareholder return plans, and authorization for the board to handle issuance matters. It is a formal review and approval opinion rather than a financial report or announcement of results. The document length is 3088 characters, relatively short and focused on the issuance process and supervisory board's audit opinion. This fits the category of Capital/Financing Update (CAP) as it relates to company fundraising and issuance activities.
2023-02-27 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.